Vir Biotechnology (VIR) Competitors $5.70 -0.07 (-1.13%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIR vs. IMVT, KYMR, CRNX, MOR, ALVO, RXRX, MIRM, CPRX, NAMS, and GMTXShould you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Immunovant (IMVT), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Recursion Pharmaceuticals (RXRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), NewAmsterdam Pharma (NAMS), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Vir Biotechnology vs. Its Competitors Immunovant Kymera Therapeutics Crinetics Pharmaceuticals MorphoSys Alvotech Recursion Pharmaceuticals Mirum Pharmaceuticals Catalyst Pharmaceuticals NewAmsterdam Pharma Gemini Therapeutics Vir Biotechnology (NASDAQ:VIR) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Do analysts rate VIR or IMVT? Vir Biotechnology presently has a consensus target price of $30.25, suggesting a potential upside of 431.17%. Immunovant has a consensus target price of $36.30, suggesting a potential upside of 112.55%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Vir Biotechnology is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vir Biotechnology 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Immunovant 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82 Do institutionals and insiders hold more shares of VIR or IMVT? 65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 16.0% of Vir Biotechnology shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor VIR or IMVT? In the previous week, Vir Biotechnology had 6 more articles in the media than Immunovant. MarketBeat recorded 7 mentions for Vir Biotechnology and 1 mentions for Immunovant. Immunovant's average media sentiment score of 1.89 beat Vir Biotechnology's score of 0.81 indicating that Immunovant is being referred to more favorably in the news media. Company Overall Sentiment Vir Biotechnology Positive Immunovant Very Positive Is VIR or IMVT more profitable? Immunovant has a net margin of 0.00% compared to Vir Biotechnology's net margin of -2,769.04%. Vir Biotechnology's return on equity of -47.46% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Vir Biotechnology-2,769.04% -47.46% -39.33% Immunovant N/A -80.60%-71.89% Which has more volatility & risk, VIR or IMVT? Vir Biotechnology has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Which has preferable earnings and valuation, VIR or IMVT? Immunovant has lower revenue, but higher earnings than Vir Biotechnology. Immunovant is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVir Biotechnology$74.21M10.61-$521.96M-$4.22-1.35ImmunovantN/AN/A-$413.84M-$2.74-6.23 SummaryVir Biotechnology beats Immunovant on 10 of the 15 factors compared between the two stocks. Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIR vs. The Competition Export to ExcelMetricVir BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$785.89M$3.04B$5.72B$9.52BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-1.3521.1228.0720.02Price / Sales10.61340.60462.58104.32Price / CashN/A43.2336.5558.97Price / Book0.688.338.645.90Net Income-$521.96M-$55.19M$3.24B$258.50M7 Day Performance5.27%5.91%4.08%2.12%1 Month Performance9.73%17.69%10.68%12.62%1 Year Performance-46.58%5.36%34.47%19.25% Vir Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRVir Biotechnology3.6999 of 5 stars$5.70-1.1%$30.25+431.2%-43.0%$785.89M$74.21M-1.35580Upcoming EarningsIMVTImmunovant1.628 of 5 stars$17.70-1.2%$36.30+105.1%-34.4%$3.03BN/A-6.46120Positive NewsGap DownKYMRKymera Therapeutics3.0163 of 5 stars$45.14-2.3%$59.11+31.0%+6.9%$2.94B$47.07M-14.56170Positive NewsCRNXCrinetics Pharmaceuticals3.6781 of 5 stars$30.95-0.5%$69.50+124.6%-43.1%$2.90B$1.04M-8.10210Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ALVOAlvotech2.8352 of 5 stars$8.64+0.1%$16.00+85.2%-21.0%$2.60B$491.98M23.351,032RXRXRecursion Pharmaceuticals1.4367 of 5 stars$6.40+9.6%$7.00+9.4%-19.8%$2.60B$58.84M-3.62400High Trading VolumeMIRMMirum Pharmaceuticals3.8551 of 5 stars$51.95+0.0%$65.50+26.1%+33.5%$2.57B$336.89M-32.27140Positive NewsCPRXCatalyst Pharmaceuticals4.9232 of 5 stars$21.01-0.1%$32.83+56.3%+20.0%$2.56B$491.73M13.3880News CoveragePositive NewsAnalyst RevisionNAMSNewAmsterdam Pharma3.7852 of 5 stars$22.56+1.6%$41.30+83.1%+23.8%$2.53B$45.56M-12.004GMTXGemini TherapeuticsN/A$57.770.0%N/A+32.1%$2.50BN/A-57.7730High Trading Volume Related Companies and Tools Related Companies IMVT Alternatives KYMR Alternatives CRNX Alternatives MOR Alternatives ALVO Alternatives RXRX Alternatives MIRM Alternatives CPRX Alternatives NAMS Alternatives GMTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIR) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIR Stock Alerts